Tag: OMEICOS

OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

BERLIN & BOSTON–(BUSINESS WIRE)–OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of Christian Schetter, Ph.D., as an independent Board Member. Christian has over 20 years’ industry experience across the life sciences sector, and most […]

Forbion Leads €17M Series C Financing of Omeicos Therapeutics

NAARDEN, Netherlands, & MUNICH–(BUSINESS WIRE)–Forbion, a leading European life science venture capital firm, today announces that it has led a €17m Series C financing of OMEICOS Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin, Germany. Forbion is the only new investor participating in the financing round, contributing €12.5m […]

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

BERLIN–(BUSINESS WIRE)–OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced results from its first-in-human clinical study for OMT-28. The study met its primary goal with OMT-28 exhibiting an excellent tolerability profile and showing no safety signals […]